Starpharma Holdings Ltd
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company's products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurr… Read more
Starpharma Holdings Ltd (SPHRY) - Net Assets
Latest net assets as of June 2025: $19.00 Million USD
Based on the latest financial reports, Starpharma Holdings Ltd (SPHRY) has net assets worth $19.00 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($25.42 Million) and total liabilities ($6.42 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $19.00 Million |
| % of Total Assets | 74.73% |
| Annual Growth Rate | -4.88% |
| 5-Year Change | -69.51% |
| 10-Year Change | -61.56% |
| Growth Volatility | 37.35 |
Starpharma Holdings Ltd - Net Assets Trend (2014–2025)
This chart illustrates how Starpharma Holdings Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Starpharma Holdings Ltd (2014–2025)
The table below shows the annual net assets of Starpharma Holdings Ltd from 2014 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $19.00 Million | -32.43% |
| 2024-06-30 | $28.12 Million | -19.24% |
| 2023-06-30 | $34.81 Million | -28.06% |
| 2022-06-30 | $48.39 Million | -22.32% |
| 2021-06-30 | $62.30 Million | +98.88% |
| 2020-06-30 | $31.33 Million | -26.11% |
| 2019-06-30 | $42.40 Million | -20.43% |
| 2018-06-30 | $53.28 Million | -12.64% |
| 2017-06-30 | $60.98 Million | +23.39% |
| 2016-06-30 | $49.42 Million | +18.16% |
| 2015-06-30 | $41.83 Million | +26.94% |
| 2014-06-30 | $32.95 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Starpharma Holdings Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 14010300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $271.35 Million | 1428.31% |
| Total Equity | $19.00 Million | 100.00% |
Starpharma Holdings Ltd Competitors by Market Cap
The table below lists competitors of Starpharma Holdings Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Stratus Properties Inc
NASDAQ:STRS
|
$151.18 Million |
|
TaTaTu SpA
PA:ALTTU
|
$151.21 Million |
|
First Capital Inc
NASDAQ:FCAP
|
$151.22 Million |
|
VAN DE VELDE (NACH AUFT.)
F:VO4
|
$151.23 Million |
|
d'Amico International Shipping S.A
OTCQX:DMCOF
|
$151.15 Million |
|
Suzhou Iron Technology Co. Ltd. A
SHG:688329
|
$151.12 Million |
|
Power Solutions International Inc
PINK:PSIX
|
$151.12 Million |
|
DONGJIANG ENVIRONMENTAL H
F:DGN
|
$151.06 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Starpharma Holdings Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 28,116,000 to 18,998,000, a change of -9,118,000 (-32.4%).
- Net loss of 9,990,000 reduced equity.
- Other factors increased equity by 872,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-9.99 Million | -52.58% |
| Other Changes | $872.00K | +4.59% |
| Total Change | $- | -32.43% |
Book Value vs Market Value Analysis
This analysis compares Starpharma Holdings Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 12.99x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-06-30 | $0.00 | $0.59 | x |
| 2017-06-30 | $0.17 | $0.59 | x |
| 2018-06-30 | $0.14 | $0.59 | x |
| 2019-06-30 | $0.11 | $0.59 | x |
| 2020-06-30 | $0.08 | $0.59 | x |
| 2021-06-30 | $0.15 | $0.59 | x |
| 2022-06-30 | $0.12 | $0.59 | x |
| 2023-06-30 | $0.08 | $0.59 | x |
| 2024-06-30 | $0.07 | $0.59 | x |
| 2025-06-30 | $0.05 | $0.59 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Starpharma Holdings Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -52.58%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -203.38%
- • Asset Turnover: 0.19x
- • Equity Multiplier: 1.34x
- Recent ROE (-52.58%) is below the historical average (-34.89%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -44.41% | -1168.00% | 0.03x | 1.12x | $-17.93 Million |
| 2015 | -50.46% | -1116.68% | 0.04x | 1.18x | $-25.29 Million |
| 2016 | -45.88% | -592.81% | 0.06x | 1.19x | $-27.62 Million |
| 2017 | 13.45% | 274.06% | 0.04x | 1.09x | $2.10 Million |
| 2018 | -19.30% | -269.81% | 0.07x | 1.10x | $-15.61 Million |
| 2019 | -33.62% | -863.36% | 0.03x | 1.15x | $-18.49 Million |
| 2020 | -46.86% | -243.30% | 0.15x | 1.25x | $-17.81 Million |
| 2021 | -31.67% | -1097.44% | 0.02x | 1.18x | $-25.96 Million |
| 2022 | -33.38% | -345.02% | 0.07x | 1.37x | $-20.99 Million |
| 2023 | -44.92% | -532.09% | 0.06x | 1.50x | $-19.12 Million |
| 2024 | -29.04% | -98.50% | 0.23x | 1.31x | $-10.98 Million |
| 2025 | -52.58% | -203.38% | 0.19x | 1.34x | $-11.89 Million |
Industry Comparison
This section compares Starpharma Holdings Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Starpharma Holdings Ltd (SPHRY) | $19.00 Million | -44.41% | 0.34x | $151.17 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |